A. Rodgers

发表

Age Effects on Placebo Response Rates in Clinical Trials of Acute Agents for Migraine: Pooled Analysis of Rizatriptan Trials in Adults

C. Lines, R. Shapiro, T. Ho, 2009, Cephalalgia : an international journal of headache.

Treatment of hospitalized patients with complicated gram-positive skin and skin structure infections: two randomized, multicentre studies of quinupristin/dalfopristin versus cefazolin, oxacillin or vancomycin. Synercid Skin and Skin Structure Infection Group.

S. Wilson, D. Dunn, M. Zervos, 1999, The Journal of antimicrobial chemotherapy.

Association between First-Year Virological Response to Raltegravir and Long-Term Outcomes in Treatment-Experienced Patients with HIV-1 Infection

B. Clotet, D. Cooper, R. Steigbigel, 2015, Antiviral therapy.

Doravirine dose Selection and 96-Week Safety and Efficacy versus Efavirenz in Antiretroviral Therapy-Naive Adults with HIV-1 Infection in a Phase IIb Trial

J. Gatell, H. Teppler, F. Raffi, 2019, Antiviral therapy.

Once-Daily Doravirine in HIV-1-Infected, Antiretroviral-Naive Adults: An Integrated Efficacy Analysis.

C. Orkin, A. Rodgers, J. Molina, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial.

P. Sax, K. Squires, P. Cahn, 2019, The lancet. HIV.

Influence of Sex/Gender and Race on Responses to Raltegravir Combined With Tenofovir-Emtricitabine in Treatment-Naive Human Immunodeficiency Virus-1 Infected Patients: Pooled Analyses of the STARTMRK and QDMRK Studies

C. Katlama, Y. Yazdanpanah, K. Squires, 2017, Open forum infectious diseases.

Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK.

A. Lazzarin, M. Saag, J. Rockstroh, 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Efficacy and tolerability of aprepitant for the prevention of chemotherapy‐induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy

H. Muss, A. Rodgers, F. Skobieranda, 2005, Cancer.

Oral abstracts of the 21st International AIDS Conference 18–22 July 2016, Durban, South Africa

Michael I. Jordan, Donald A. Jackson, J. G. Ndirangu, 2016, Journal of the International AIDS Society.

Efficacy and tolerability of finasteride 1 mg in men aged 41 to 60 years with male pattern hair loss.

A. Rodgers, E. Olsen, D. Whiting, 2003, European journal of dermatology : EJD.

Safety and efficacy at 240 weeks of different raltegravir formulations in children with HIV-1: a phase 1/2 open label, non-randomised, multicentre trial.

H. Teppler, A. Rodgers, S. Nachman, 2018, The lancet. HIV.

Safety, tolerability, and efficacy of raltegravir in a diverse cohort of HIV-infected patients: 48-week results from the REALMRK Study.

K. Mounzer, K. Squires, L. Bekker, 2013, AIDS research and human retroviruses.

Efficacy of Raltegravir Versus Efavirenz When Combined With Tenofovir/ Emtricitabine in Treatment-Naïve HIV-1–Infected Patients: Week-192 Overall and Subgroup Analyses From STARTMRK

A. Lazzarin, M. Saag, J. Rockstroh, 2012, HIV clinical trials.

Symptoms of Cutaneous Sensitivity Pre-Treatment and Post-Treatment: Results from the Rizatriptan TAME Studies

R. Cady, A. Rodgers, F. Skobieranda, 2007, Cephalalgia : an international journal of headache.

Rizatriptan 10‐mg ODT for Early Treatment of Migraine and Impact of Migraine Education on Treatment Response

K. Connor, R. Cady, T. Ho, 2009, Headache.

Rizatriptan Efficacy in ICHD‐II Pure Menstrual Migraine and Menstrually Related Migraine

A. Rodgers, F. Skobieranda, C. Hustad, 2008, Headache.

Efficacy and Tolerability of Coadministration of Rizatriptan and Acetaminophen vs Rizatriptan or Acetaminophen Alone for Acute Migraine Treatment

I. Janssen, A. Rodgers, F. Skobieranda, 2008, Headache.

The efficacy of rofecoxib 50 mg and hydrocodone/acetaminophen 7.5/750 mg in patients with post-arthroscopic pain

C. Nissen, J. Chelly, A. Rodgers, 2007, Current medical research and opinion.

Rizatriptan for the Acute Treatment of ICHD-II Proposed Menstrual Migraine: Two Prospective, Randomized, Placebo-Controlled, Double-Blind Studies

E. Loder, A. Rodgers, F. Skobieranda, 2007, Cephalalgia : an international journal of headache.

Global photographic assessment of men aged 18 to 60 years with male pattern hair loss receiving finasteride 1 mg or placebo.

A. Rodgers, E. Round, K. Kaufman, 2012, Journal of the American Academy of Dermatology.

Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial

Adriano Lazzarin, Edwin DeJesus, Peter Sklar, 2009, The Lancet.

Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial.

C. Katlama, P. Sax, Y. Yazdanpanah, 2017, The lancet. HIV.

Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial.

Jing Zhao, Christine Katlama, Benjamin Young, 2011, The Lancet. Infectious diseases.

Durable Efficacy and Safety of Raltegravir Versus Efavirenz When Combined With Tenofovir/Emtricitabine in Treatment-Naive HIV-1–Infected Patients: Final 5-Year Results From STARTMRK

Y. Yazdanpanah, M. Saag, J. Rockstroh, 2013, Journal of acquired immune deficiency syndromes.

Efficacy and Safety of Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) in Treatment-Naive Adults With HIV-1 and Transmitted Nonnucleoside Reverse Transcriptase Inhibitor Resistance Mutations

H. Teppler, Valerie Teal, J. Mallolas, 2019, Journal of acquired immune deficiency syndromes.

Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate is Non-inferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-naive Adults With Human Immunodeficiency Virus–1 Infection: Week 48 Results of the DRIVE-AHEAD Trial

P. Sax, K. Squires, C. Orkin, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial.

P. Sax, K. Squires, P. Cahn, 2018, The lancet. HIV.

Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials

D. Cooper, M. Youle, R. Leavitt, 2010, The Lancet.

Efficacy, safety and central nervous system effects after switch from efavirenz/tenofovir/emtricitabine to doravirine/tenofovir/lamivudine

A. Winston, H. Teppler, Valerie Teal, 2020, AIDS.

Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy.

R. Gralla, H. Muss, A. Rodgers, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK

Raúl Tabarés Gutiérrez, Samit R. Joshi, H. Jessen, 2016, Journal of the International AIDS Society.

Raltegravir Versus Efavirenz Regimens in Treatment-Naive HIV-1–Infected Patients: 96-Week Efficacy, Durability, Subgroup, Safety, and Metabolic Analyses

A. Lazzarin, Jinrong Zhao, R. Leavitt, 2010, Journal of acquired immune deficiency syndromes.

Effect of aprepitant for the prevention of nausea and vomiting after one cycle of moderately emetogenic chemotherapy: A randomized double-blind trial in 866 patients.

R. Gralla, H. Muss, A. Rodgers, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Analysis of BENCHMRK 1 & 2 using PhenoSense® assay for darunavir (DRV/r) resistance and exploration of functional monotherapy with RAL vs DRV

R. Steigbigel, H. Teppler, J. Rockstroh, 2010, Journal of the International AIDS Society.

Impact of Recent Prior Opioid Use on Rizatriptan Efficacy. A Post Hoc Pooled Analysis

T. Ho, A. Rodgers, M. Bigal, 2009, Headache.

Different impact of raltegravir versus efavirenz on CD4/CD8 ratio recovery in HIV-infected patients

A. Rodgers, S. Moreno, Yan Zhou, 2017, The Journal of antimicrobial chemotherapy.

Initial treatment with a single pill containing quadruple combination of quarter doses of blood pressure medicines versus standard dose monotherapy in patients with hypertension (QUARTET): a phase 3, randomised, double-blind, active-controlled trial

G. Hillis, M. Nelson, G. Figtree, 2021, The Lancet.

Efficacy of Rizatriptan for Menstrual Migraine in an Early Intervention Model: A Prospective Subgroup Analysis of the Rizatriptan TAME (Treat A Migraine Early) Studies

R. Cady, A. Rodgers, F. Skobieranda, 2007, Headache.

Expanding Access to Triptans: Assessment of Clinical Outcome

S. Silberstein, R. Cady, T. Ho, 2009, Headache.

Efficacy of Rizatriptan 10 mg Administered Early in a Migraine Attack

R. Cady, A. Rodgers, F. Skobieranda, 2006, Headache.

Pharmacokinetic Profile of Rizatriptan 10‐mg Tablet and 10‐mg Orally Disintegrating Tablet Administered With or Without Water in Healthy Subjects: An Open‐Label, Randomized, Single‐Dose, 3‐Period Crossover Study

S. Swan, A. Rodgers, F. Skobieranda, 2006, Journal of clinical pharmacology.

Comment on Eletriptan in Migraine Patients Reporting Unsatisfactory Response to Rizatriptan

A. Rodgers, F. Skobieranda, K. Ramsey, 2007, Headache.

Elimination of Migraine‐Associated Nausea in Patients Treated with Rizatriptan Orally Disintegrating Tablet (ODT): A Randomized, Double‐Blind, Placebo‐Controlled Study

A. Rodgers, F. Skobieranda, F. Freitag, 2008, Headache.

Once-Daily Doravirine for Initial Treatment of Adults Living With HIV-1: An Integrated Safety Analysis.

P. Sax, K. Squires, P. Cahn, 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Efficacy and safety of rofecoxib 12.5 mg and celecoxib 200 mg in two similarly designed osteoarthritis studies

A. Rodgers, C. Birbara, G. Ruoff, 2006, Current medical research and opinion.

Total Migraine Freedom, a Potential Primary Endpoint to Assess Acute Treatment in Migraine: Comparison to the Current FDA Requirement Using the Complete Rizatriptan Study Database

R. Cady, T. Ho, A. Rodgers, 2011, Headache.

Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): randomised double-blind active-controlled trial

P. Mitchell, P. Riva-Posse, B. Baune, 2023, The British Journal of Psychiatry.

Efficacy, safety and CNS effects after switch from efavirenz/tenofovir/emtricitabine to doravirine/tenofovir/lamivudine in a randomized controlled trial.

A. Winston, H. Teppler, Valerie Teal, 2021, AIDS.

Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial

A. Lazzarin, R. Leavitt, R. Pollard, 2009, The Lancet.

Rizatriptan Efficacy in ICHD‐II Pure Menstrual Migraine and Menstrually Related Migraine

A. Rodgers, F. Skobieranda, C. Hustad, 2008, Headache.

543. An Integrated Safety Analysis Comparing Once-Daily Doravirine (DOR) to Darunavir+Ritonavir (DRV+r) and Efavirenz (EFV) in HIV-1-Infected, Antiretroviral Therapy (ART)-Naïve Adults

P. Sax, J. Gatell, K. Squires, 2018, Open Forum Infectious Diseases.

Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK.

A. Lazzarin, M. Saag, J. Rockstroh, 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.